184 related articles for article (PubMed ID: 18025156)
21. A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490.
Caceres-Cortes JR
Anticancer Agents Med Chem; 2008 Oct; 8(7):717-22. PubMed ID: 18855573
[TBL] [Abstract][Full Text] [Related]
22. Functional analysis of focal adhesion kinase (FAK) reduction by small inhibitory RNAs.
Han EK; Mcgonigal T; Wang J; Giranda VL; Luo Y
Anticancer Res; 2004; 24(6):3899-905. PubMed ID: 15736429
[TBL] [Abstract][Full Text] [Related]
23. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
Levis M; Allebach J; Tse KF; Zheng R; Baldwin BR; Smith BD; Jones-Bolin S; Ruggeri B; Dionne C; Small D
Blood; 2002 Jun; 99(11):3885-91. PubMed ID: 12010785
[TBL] [Abstract][Full Text] [Related]
24. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
Liu KD; Gaffen SL; Goldsmith MA; Greene WC
Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
[TBL] [Abstract][Full Text] [Related]
25. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Hu X; Chen F
Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
[No Abstract] [Full Text] [Related]
26. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
27. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.
Caligiuri MA; Briesewitz R; Yu J; Wang L; Wei M; Arnoczky KJ; Marburger TB; Wen J; Perrotti D; Bloomfield CD; Whitman SP
Blood; 2007 Aug; 110(3):1022-4. PubMed ID: 17475912
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Megías-Vericat JE; Ballesta-López O; Barragán E; Martínez-Cuadrón D; Montesinos P
Blood Rev; 2020 Nov; 44():100675. PubMed ID: 32147087
[TBL] [Abstract][Full Text] [Related]
29. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
[TBL] [Abstract][Full Text] [Related]
30. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.
Mercher T; Wernig G; Moore SA; Levine RL; Gu TL; Fröhling S; Cullen D; Polakiewicz RD; Bernard OA; Boggon TJ; Lee BH; Gilliland DG
Blood; 2006 Oct; 108(8):2770-9. PubMed ID: 16804112
[TBL] [Abstract][Full Text] [Related]
31. Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression.
Hirano T; Yoshikawa R; Harada H; Harada Y; Ishida A; Yamazaki T
Mol Cancer; 2015 Apr; 14():90. PubMed ID: 25928165
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
[TBL] [Abstract][Full Text] [Related]
33. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia.
Xiang Z; Zhao Y; Mitaksov V; Fremont DH; Kasai Y; Molitoris A; Ries RE; Miner TL; McLellan MD; DiPersio JF; Link DC; Payton JE; Graubert TA; Watson M; Shannon W; Heath SE; Nagarajan R; Mardis ER; Wilson RK; Ley TJ; Tomasson MH
Blood; 2008 May; 111(9):4809-12. PubMed ID: 18160671
[TBL] [Abstract][Full Text] [Related]
34. Focal Adhesion Kinase as a Potential Target in AML and MDS.
Carter BZ; Mak PY; Wang X; Yang H; Garcia-Manero G; Mak DH; Mu H; Ruvolo VR; Qiu Y; Coombes K; Zhang N; Ragon B; Weaver DT; Pachter JA; Kornblau S; Andreeff M
Mol Cancer Ther; 2017 Jun; 16(6):1133-1144. PubMed ID: 28270436
[TBL] [Abstract][Full Text] [Related]
35. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.
Witthuhn BA; Williams MD; Kerawalla H; Uckun FM
Leuk Lymphoma; 1999 Jan; 32(3-4):289-97. PubMed ID: 10037026
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
37. Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells.
Arseni N; Ahmed F; Hiddemann W; Buske C; Feuring-Buske M
Haematologica; 2005 Nov; 90(11):1577-8. PubMed ID: 16266907
[TBL] [Abstract][Full Text] [Related]
38. Receptor tyrosine kinase alterations in AML - biology and therapy.
Stirewalt DL; Meshinchi S
Cancer Treat Res; 2010; 145():85-108. PubMed ID: 20306247
[TBL] [Abstract][Full Text] [Related]
39. Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target.
Aka Y; Karakas B; Acikbas U; Basaga H; Gul O; Kutuk O
Int J Biochem Cell Biol; 2021 Aug; 137():106028. PubMed ID: 34171479
[TBL] [Abstract][Full Text] [Related]
40. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.
Abbaspour Babaei M; Kamalidehghan B; Saleem M; Huri HZ; Ahmadipour F
Drug Des Devel Ther; 2016; 10():2443-59. PubMed ID: 27536065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
